239 related articles for article (PubMed ID: 24811162)
21. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
[TBL] [Abstract][Full Text] [Related]
22. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy.
Buggy JJ; Elias L
Int Rev Immunol; 2012 Apr; 31(2):119-32. PubMed ID: 22449073
[TBL] [Abstract][Full Text] [Related]
23. MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications.
de Groen RAL; Schrader AMR; Kersten MJ; Pals ST; Vermaat JSP
Haematologica; 2019 Dec; 104(12):2337-2348. PubMed ID: 31699794
[TBL] [Abstract][Full Text] [Related]
24. Developing novel strategies to target B-cell malignancies.
Fowler N; Oki Y
Am Soc Clin Oncol Educ Book; 2013; ():366-72. PubMed ID: 23714549
[TBL] [Abstract][Full Text] [Related]
25. Driving toward precision medicine for B cell lymphomas: Targeting the molecular pathogenesis at the gene level.
Chung C
J Oncol Pharm Pract; 2020 Jun; 26(4):943-966. PubMed ID: 31964218
[TBL] [Abstract][Full Text] [Related]
26. New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice.
Mullighan CG
Clin Cancer Res; 2011 Feb; 17(3):396-400. PubMed ID: 21149616
[TBL] [Abstract][Full Text] [Related]
27. Targeting oncogenic and epigenetic survival pathways in lymphoma.
Leslie LA; Younes A
Leuk Lymphoma; 2013 Nov; 54(11):2365-76. PubMed ID: 23442067
[TBL] [Abstract][Full Text] [Related]
28. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
29. Lymphoma study group of JCOG.
Tsukasaki K; Tobinai K; Hotta T; Shimoyama M
Jpn J Clin Oncol; 2012 Feb; 42(2):85-95. PubMed ID: 22147803
[TBL] [Abstract][Full Text] [Related]
30. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.
Frau M; Feo F; Pascale RM
J Hepatol; 2013 Oct; 59(4):830-41. PubMed ID: 23665184
[TBL] [Abstract][Full Text] [Related]
31. New drugs for the treatment of advanced-stage diffuse large cell lymphomas.
O'Connor OA; Hamlin P
Semin Hematol; 2006 Oct; 43(4):251-61. PubMed ID: 17027659
[TBL] [Abstract][Full Text] [Related]
32. The molecular background of aggressive B cell lymphomas as a basis for targeted therapy.
de Jong D; Balagué Ponz O
J Pathol; 2011 Jan; 223(2):274-82. PubMed ID: 21125680
[TBL] [Abstract][Full Text] [Related]
33. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.
Blachly JS; Baiocchi RA
Br J Haematol; 2014 Oct; 167(1):19-32. PubMed ID: 25100567
[TBL] [Abstract][Full Text] [Related]
34. Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance.
Maxwell SA; Mousavi-Fard S
Exp Biol Med (Maywood); 2013 Sep; 238(9):971-90. PubMed ID: 23986223
[TBL] [Abstract][Full Text] [Related]
35. Signal transduction inhibitors in chronic lymphocytic leukemia.
Ma S; Rosen ST
Curr Opin Oncol; 2011 Nov; 23(6):601-8. PubMed ID: 21892084
[TBL] [Abstract][Full Text] [Related]
36. Gamma-secretase inhibitors suppress the growth of leukemia and lymphoma cells.
Kogoshi H; Sato T; Koyama T; Nara N; Tohda S
Oncol Rep; 2007 Jul; 18(1):77-80. PubMed ID: 17549349
[TBL] [Abstract][Full Text] [Related]
37. MYC and aggressive B-cell lymphomas.
Slack GW; Gascoyne RD
Adv Anat Pathol; 2011 May; 18(3):219-28. PubMed ID: 21490439
[TBL] [Abstract][Full Text] [Related]
38. Bruton Tyrosine Kinase Degraders in B-Cell Malignancies.
Huynh T; Rodriguez-Rodriguez S; Danilov AV
Mol Cancer Ther; 2024 May; 23(5):619-626. PubMed ID: 38693903
[No Abstract] [Full Text] [Related]
39. Utilization of the Eμ-Myc mouse to model heterogeneity of therapeutic response.
Rempel RE; Jiang X; Fullerton P; Tan TZ; Ye J; Lau JA; Mori S; Chi JT; Nevins JR; Friedman DR
Mol Cancer Ther; 2014 Dec; 13(12):3219-29. PubMed ID: 25349303
[TBL] [Abstract][Full Text] [Related]
40. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.
Hummel M; Bentink S; Berger H; Klapper W; Wessendorf S; Barth TF; Bernd HW; Cogliatti SB; Dierlamm J; Feller AC; Hansmann ML; Haralambieva E; Harder L; Hasenclever D; Kühn M; Lenze D; Lichter P; Martin-Subero JI; Möller P; Müller-Hermelink HK; Ott G; Parwaresch RM; Pott C; Rosenwald A; Rosolowski M; Schwaenen C; Stürzenhofecker B; Szczepanowski M; Trautmann H; Wacker HH; Spang R; Loeffler M; Trümper L; Stein H; Siebert R;
N Engl J Med; 2006 Jun; 354(23):2419-30. PubMed ID: 16760442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
